Skip to main content
Targeting misfolded SOD1 to change the course of ALS

Because every moment matters for those living with ALS and those who care for them

About AL-S Pharma

AL-S Pharma is advancing AP-101, a first-in-class antibody designed to deplete misfolded SOD1 in both sporadic ALS and SOD1-ALS.

In 2025, the company completed a Phase 2 clinical trial of AP-101 with positive results.

About ALS

Amyotrophic lateral sclerosis (ALS) is a relentless and progressive neurodegenerative disease that affects the motor neurons of the brain and spinal cord. While symptoms vary from person to person, all forms ultimately lead to loss of independence and a markedly shortened lifespan.

About AP-101

AP-101 is a recombinant human antibody designed to selectively deplete toxic, misfolded forms of SOD1 while preserving the protective function of physiological SOD1. By targeting only the pathological conformations, AP-101 aims to disrupt a key driver of ALS progression without lowering total SOD1 levels.

«At AL-S Pharma, we are driven by the urgent need for effective therapies in ALS. The progress of AP-101 reflects our commitment to translating scientific innovation into clinical advances for patients and families affected by this devastating disease.»

Michael Salzmann, PhD
CEO

Explore the news & events


January 07, 2026
AL-S Pharma to present at the upcoming J. P. Morgan 2026 Annual Healthcare Conference on Thursday, January 15
December 05, 2025
AL-S Pharma Reports Positive Results from Phase 2 Study of AP-101 for the Treatment of ALS, Supporting Plans for a Confirmatory Phase 3 Study
July 12-15, 2026
21st Alzheimer’s Association International Conference